In addition, excluding the MDA5 positivity that was checked in all patients, data regarding other immunological assays may be lacking in our patients, especially regarding anti-Ro52 positivity which is associated with poor outcomes in RP-ILD patients (25). This evidence concerns the gene IFIH1 and interstitial lung disease.